Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 95 (43), e5040

Clinical Effect of DAPK Promoter Methylation in Gastric Cancer: A Systematic Meta-Analysis

Affiliations
Review

Clinical Effect of DAPK Promoter Methylation in Gastric Cancer: A Systematic Meta-Analysis

Wenzhuo Jia et al. Medicine (Baltimore).

Abstract

Background: The loss of death-associated protein kinase (DAPK) gene expression through promoter methylation is involved in many tumors. However, the relationship between DAPK promoter methylation and clinicopathological features of gastric cancer (GC) remains to be done. Therefore, we performed a meta-analysis to assess the role of DAPK promoter methylation in GC.

Methods: Literature databases were searched to retrieve eligible studies. The pooled odds ratios (ORs) with its 95% confidence intervals (CIs) were calculated using the Stata 12.0 software.

Results: Final 22 available studies with 1606 GC patients and 1508 nonmalignant controls were analyzed. A significant correlation was found between DAPK promoter methylation and GC (OR = 3.23, 95% CI = 1.70-6.14, P < 0.001), but we did not find any significant association in Caucasian population, and in blood samples in subgroup analyses. DAPK promoter methylation was associated with tumor stage and lymph node status (OR = 0.69, 95% CI = 0.49-0.96, P = 0.03; OR = 1.50, 95% CI = 1.12-2.01, P = 0.007; respectively). However, we did not find that DAPK promoter methylation was associated with gender status and tumor histology.

Conclusion: Our findings suggested that DAPK promoter methylation may play a key role in the carcinogenesis and progression of GC. In addition, methylated DAPK was a susceptible gene for Asian population. However, more studies with larger subjects should be done to further evaluate the effect of DAPK promoter methylation in GC patients, especially in blood and Caucasian population subgroup.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of the literature search strategy.
Figure 2
Figure 2
Forest plot of DAPK promoter methylation in GC versus nonmalignant controls. DAPK = death-associated protein kinase, GC = gastric cancer.
Figure 3
Figure 3
Forest plot of the association between DAPK promoter methylation and tumor stage. DAPK = death-associated protein kinase.
Figure 4
Figure 4
Forest plot of the association between DAPK promoter methylation and lymph node status. DAPK = death-associated protein kinase.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87–108. - PubMed
    1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12:354–362. - PMC - PubMed
    1. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424:53–65. - PubMed
    1. Tahara T, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer. Epigenomics 2015; 7:475–486. - PubMed
    1. Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J 2014; 55:621–628. - PMC - PubMed

MeSH terms

Substances

Feedback